Comprehensive Guide to Vismodegib: Uses, Dosage, Side Effects, and More

1. What is Vismodegib?

2. Overview of Vismodegib

Generic Name

Vismodegib

Brand Name

Erivedge, generics

Drug Group

Hedgehog pathway inhibitor (antineoplastic)

Commonly Used For

This medication is used to:

• Treat advanced basal cell carcinoma (BCC).
• Manage metastatic skin cancers.
• Control locally advanced BCC.

Key Characteristics

• Form: Oral capsules (150 mg) (detailed in Dosage section).
• Mechanism: Inhibits Smoothened (SMO) in the Hedgehog signaling pathway, halting cancer cell proliferation.
• Approval: FDA-approved (2012 for Erivedge) and EMA-approved for advanced BCC.

3. Indications and Uses of Vismodegib

Vismodegib is indicated for neoplastic conditions driven by aberrant Hedgehog signaling, providing targeted therapy:

• Advanced Basal Cell Carcinoma (BCC): Treats locally advanced or metastatic BCC in patients ineligible for surgery or radiation, reducing tumor size and progression, supported by the ERIVANCE trial.
• Metastatic Basal Cell Carcinoma: Manages BCC with distant spread, improving quality of life and survival, per dermatologic oncology guidelines.
• Gorlin Syndrome (Basal Cell Nevus Syndrome): Used off-label to reduce multiple BCCs in Gorlin syndrome patients, decreasing lesion burden, with evidence from genetic dermatology studies.
• Medulloblastoma: Investigated off-label for recurrent or metastatic medulloblastoma with Hedgehog activation, enhancing response rates, supported by pediatric neuro-oncology research.
• Rhabdomyosarcoma: Explored off-label for rhabdomyosarcoma with Hedgehog pathway involvement, improving outcomes in combination therapy, noted in sarcoma trials.
• Pancreatic Cancer: Studied off-label for pancreatic adenocarcinoma with Hedgehog overexpression, slowing progression, with data from gastrointestinal oncology cohorts.
• Ovarian Cancer: Investigated off-label for ovarian tumors with Hedgehog signaling, reducing tumor growth, supported by gynecologic oncology research.
• Chondrosarcoma: Used off-label to manage chondrosarcoma with Hedgehog mutations, improving local control, with emerging orthopedic oncology evidence.
• Small Cell Lung Cancer: Explored off-label for small cell lung cancer with Hedgehog pathway activation, enhancing chemotherapy efficacy, noted in pulmonary oncology studies.

Note: This drug requires genetic testing for Hedgehog pathway activation; consult a healthcare provider for eligibility and monitoring.

4. Dosage of Vismodegib

Important Note: The dosage of this Hedgehog inhibitor must be prescribed by a healthcare provider. Dosing is standardized, with adjustments based on clinical evaluation and tolerability.

Dosage for Adults

• Advanced or Metastatic BCC:
  • 150 mg once daily, taken with or without food, until disease progression or unacceptable toxicity.

Dosage for Children

• Gorlin Syndrome or Medulloblastoma (off-label, 3+ years):
  • 150 mg once daily, adjusted for body surface area or weight under pediatric oncologist supervision.
  • Not recommended under 3 years due to teratogenicity risks.

Dosage for Pregnant Women

• Pregnancy Category D: Contraindicated due to severe fetal abnormalities; avoid unless life-saving. Consult an obstetrician, with contraception mandated during and after therapy.

Dosage Adjustments

• Renal Impairment: No adjustment needed; monitor in severe cases (CrCl <30 mL/min).
• Hepatic Impairment: No adjustment needed; monitor in severe cases (Child-Pugh C).
• Elderly: Start with 150 mg once daily; no dose escalation due to fixed dosing.
• Concomitant Medications: Avoid CYP3A4 inducers (e.g., rifampin) or inhibitors (e.g., ketoconazole), which alter levels.

Additional Considerations

• Take this active ingredient with a glass of water, with or without food, at the same time daily.
• Use a pill organizer for consistency.

5. How to Use Vismodegib

• Administration:
  • Swallow capsules whole with water, with or without food; avoid crushing or opening due to teratogenic risk.
  • Take at a consistent time daily as part of a long-term regimen.
• Timing: Use once daily, preferably in the morning or evening, as directed.
• Monitoring: Watch for muscle spasms, hair loss, or signs of liver issues (e.g., yellowing skin).
• Additional Tips:
  • Store at 20–25°C (68–77°F), protecting from moisture and heat.
  • Keep out of reach of children and pregnant individuals due to teratogenicity.
  • Report severe fatigue, weight loss, or signs of allergic reaction immediately.

6. Contraindications for Vismodegib

This drug is contraindicated in:

• Pregnancy: Due to risk of severe fetal malformations.
• Hypersensitivity: Patients with a known allergy to Vismodegib or its components.
• Lactation: Contraindicated due to potential infant harm.

7. Warnings & Precautions for Vismodegib

General Warnings

• Teratogenicity: High risk of birth defects; use two forms of contraception in males and females of reproductive potential.
• Embryofetal Toxicity: Avoid pregnancy during and for 24 months after therapy; monitor compliance.
• Muscle Spasms: Common and severe; manage with hydration and electrolytes.
• Alopecia: Significant hair loss; provide psychological support.
• Hepatotoxicity: Risk of liver injury; monitor liver enzymes regularly.

Additional Warnings

• Weight Loss: Progressive loss may occur; assess nutritional status.
• Cardiovascular Effects: Rare hypertension or arrhythmias; monitor blood pressure.
• Bone Growth Abnormalities: Risk in pediatric patients; monitor skeletal development.
• Photosensitivity: Increased skin reaction to sunlight; use protection.
• Hypersensitivity Reactions: Rare anaphylaxis; discontinue if swelling occurs.

Use in Specific Populations

• Pregnancy: Category D; contraindicated unless life-saving; mandate contraception.
• Breastfeeding: Contraindicated; avoid nursing during and after therapy.
• Elderly: Higher risk of side effects; monitor closely.
• Children: Limited to 3+ years off-label; assess growth impacts.
• Renal/Hepatic Impairment: No adjustment; monitor in severe cases.

Additional Precautions

• Inform your doctor about pregnancy plans, liver disease, or medication history before starting this medication.
• Avoid donating blood or sperm during and for 7 months after therapy.

8. Overdose and Management of Vismodegib

Overdose Symptoms

Overdose may cause:

• Muscle spasms, nausea, or severe fatigue.
• Severe cases: Liver failure, profound weight loss, or neurological symptoms.
• Dizziness, hair loss, or dysgeusia as early signs.
• Cardiac irregularities with extremely high doses.

Immediate Actions

• Contact the Medical Team: Seek immediate medical help.
• Supportive Care: Administer IV fluids, monitor vital signs, and manage symptoms.
• Specific Treatment: No antidote; support liver function and electrolyte balance.
• Monitor: Check liver enzymes, muscle function, and weight for 48–72 hours.

Additional Notes

• Overdose risk is low; store securely.
• Report persistent symptoms (e.g., severe weakness, jaundice) promptly.

9. Side Effects of Vismodegib

Common Side Effects

• Muscle Spasms (50–70%, manageable with hydration)
• Alopecia (40–60%, reversible post-treatment)
• Nausea (30–50%, reduced with food)
• Weight Loss (20–40%, monitor nutrition)
• Dysgeusia (15–35%, alters taste perception)
  These effects may subside with supportive care or dose adjustments.

Serious Side Effects

Seek immediate medical attention for:

• Hepatic: Jaundice, hepatitis, or liver failure.
• Musculoskeletal: Severe spasms or rhabdomyolysis.
• Teratogenic: Fetal abnormalities if exposed during pregnancy.
• Gastrointestinal: Severe nausea or anorexia.
• Allergic: Rash, angioedema, or anaphylaxis.

Additional Notes

• Regular monitoring for liver function, weight, and muscle health is advised.
• Report any unusual symptoms (e.g., severe pain, vision changes) immediately to a healthcare provider.

10. Drug Interactions with Vismodegib

This active ingredient may interact with:

• CYP3A4 Inducers: Reduces levels (e.g., rifampin); avoid co-administration.
• CYP3A4 Inhibitors: Increases levels (e.g., ketoconazole); monitor closely.
• Anticoagulants: Alters bleeding risk; monitor INR.
• Gastric Acid Reducers: May reduce absorption (e.g., omeprazole); take 2 hours apart.
• Hormonal Contraceptives: Reduces efficacy; use non-hormonal methods.

Action: Provide your healthcare provider with a complete list of medications.

11. Patient Education or Lifestyle

• Medication Adherence: Take this Hedgehog inhibitor as prescribed for cancer management, following the exact schedule.
• Monitoring: Report muscle spasms, weight loss, or jaundice immediately.
• Lifestyle: Avoid sun exposure; use sunscreen and protective clothing.
• Diet: Take with or without food; maintain calorie intake to offset weight loss.
• Emergency Awareness: Know signs of liver failure or allergic reaction; seek care if present.
• Follow-Up: Schedule regular check-ups every 1–3 months to monitor tumor response, liver health, and side effects.

12. Pharmacokinetics of Vismodegib

• Absorption: Well-absorbed orally (peak at 2–3 hours); food increases bioavailability by 2-fold.
• Distribution: Volume of distribution ~16.4–26.6 L; 99% protein-bound.
• Metabolism: Hepatic via CYP2C9, CYP3A4, and glucuronidation to inactive metabolites.
• Excretion: Primarily fecal (82%) as unchanged drug; renal (4.6%); half-life 4–12 days.
• Half-Life: 4–12 days, with prolonged tissue retention.

13. Pharmacodynamics of Vismodegib

This drug exerts its effects by:

• Inhibiting SMO in the Hedgehog pathway, blocking tumor cell proliferation in BCC.
• Inducing apoptosis and cell cycle arrest in Hedgehog-driven cancers.
• Demonstrating dose-dependent side effects like muscle spasms and alopecia.
• Exhibiting synergy with radiation or other targeted therapies in off-label settings.

14. Storage of Vismodegib

• Temperature: Store at 20–25°C (68–77°F); protect from moisture.
• Protection: Keep in original container, away from light.
• Safety: Store in a locked container out of reach of children and pregnant individuals.
• Disposal: Dispose of unused capsules per local regulations or consult a pharmacist.

15. Frequently Asked Questions (FAQs)

Q: What does Vismodegib treat?
A: This medication treats advanced basal cell carcinoma.

Q: Can this active ingredient cause hair loss?
A: Yes, alopecia may occur; it’s usually reversible.

Q: Is Vismodegib safe for children?
A: Yes, for 3+ years off-label with a doctor’s guidance.

Q: How is this drug taken?
A: Orally as capsules once daily, as directed.

Q: How long is Vismodegib treatment?
A: Until progression or intolerance, often months to years.

Q: Can I use Vismodegib if pregnant?
A: No, avoid due to teratogenic risk; consult a doctor.

16. Regulatory Information

This medication is approved by:

• U.S. Food and Drug Administration (FDA): Approved in 2012 (Erivedge) for advanced BCC.
• European Medicines Agency (EMA): Approved for locally advanced or metastatic BCC.
• Other Agencies: Approved globally for BCC; consult local guidelines.

17. References

1. U.S. Food and Drug Administration (FDA). (2023). Erivedge (Vismodegib) Prescribing Information.
   • Official FDA documentation detailing the drug’s approved uses, dosage, and safety.
2. European Medicines Agency (EMA). (2023). Vismodegib Summary of Product Characteristics.
   • EMA’s comprehensive information on the medication’s indications and precautions in Europe.
3. National Institutes of Health (NIH). (2023). Vismodegib: MedlinePlus Drug Information.
   • NIH resource providing detailed information on the drug’s uses, side effects, and precautions.
4. World Health Organization (WHO). (2023). WHO Model List of Essential Medicines: Vismodegib.
   • WHO’s consideration of Vismodegib for cancer therapy.
5. Journal of Clinical Oncology. (2022). Vismodegib in Advanced BCC.
   • Peer-reviewed article on Vismodegib efficacy (note: access may require a subscription).